BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, today released an update from its Chairman, Richard Staelin, PhD, detailing sales growth, cost control achievements, and strategic advancements. The company reported a small profit for calendar year 2025, driven by disciplined cost control measures including relocation of offices and staff reductions. These efforts have aligned operations with current needs while enabling investment in initiatives to expand awareness and adoption of its technology platforms.
The company has launched targeted advertising campaigns directed at medical professionals and healthcare providers to increase clinical awareness of RecoveryRx, a non-opioid pain management device. Campaigns focus on surgeons, pain specialists, rehabilitation providers, and chiropractors. Additionally, consumer-focused social media advertising targeting Generation X consumers aims to boost brand visibility among individuals seeking drug-free solutions for chronic musculoskeletal pain. Staelin noted that these initiatives have contributed to an increase in monthly sales in both the over-the-counter and professional markets.
BioElectronics continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The goal is to participate in a postoperative clinical study that could support future qualification for reimbursement under the federal NO PAIN Act initiative, which Staelin described as a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, the company is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor that allegedly breached contractual obligations. While arbitration processes are lengthy, the company remains committed to protecting its intellectual property and contractual rights.
A significant milestone is the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, with BioElectronics receiving Electrome's initial purchase order. Manufacturing activities are underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products. Staelin emphasized that this relationship is part of a broader strategy including clinical market development, direct professional outreach, consumer education, and international opportunities.
Despite challenges faced by emerging medical technology companies, Staelin expressed encouragement by growing interest in non-drug pain management solutions and the long-term potential of the company's technology platforms. He believes BioElectronics is well positioned within the evolving electroceutical and non-opioid pain management markets and intends to continue advancing initiatives that support sustainable growth.
